

Minutes of the **Somerset Prescribing Forum** held via Microsoft Teams on **Wednesday, 8<sup>th</sup> July 2020 at 14:30p.m.**

Present:	Dr Andrew Tresidder	GP Patient Safety Lead, Somerset CCG. Chair
	Steve DuBois (SDB)	Chief Pharmacist, Somerset NHS FT
	Shaun Green (SG)	Deputy Director of Clinical Effectiveness and Medicines Management, NHS Somerset CCG
	Sam Morris (SM)	Medicines Manager, NHS Somerset CCG
	Jean Perry (JP)	Contracts Manager, NHS Somerset CCG
	Andrew Prowse (AP)	Chief Pharmacist and Controlled Drugs Accountable Officer, Yeovil NHS FT
	Caroline Taylor (CT)	Prescribing Technician, NHS Somerset CCG
Apologies:	Dr Clare Barlow (CB)	Chair D&TC, Somerset NHS FT
	Jon Beard (JB)	Chief Pharmacist, Somerset NHS FT
	Dr Orla Dunn (OD)	Public Health Representative
	Liz Harewood	Chief Pharmacist, Yeovil NHS FT
	Michaela Pinkney (MP)	Deputy Clinical Pharmacy Manager, Yeovil NHS FT

**1 INTRODUCTIONS:**

Andrew welcomed Donna Yell - Pharmacoeconomics Lead, Pharmacy Department, Yeovil District Hospital

**2 REGISTER OF MEMBERS' INTERESTS**

2.1 The Somerset Prescribing Forum received the Register of Members' Interests relevant to its membership

The Somerset Prescribing Forum noted the Register of Members' Interests

**3 Declarations of interest**

3.1 Under the CCG's arrangements for managing conflicts of interest, any member making a declaration of interest is able to participate in the discussion of the particular agenda item concerned, where appropriate, but is excluded from the decision-making and voting process if a vote is required. In these circumstances, there must be confirmation that the meeting remains quorate in order for voting to proceed. If a conflict of interest is declared by the Chairman, the agenda item in question would be chaired by a nominated member of the Somerset Prescribing Forum.

There were no declarations of interest relating to items on the agenda.

**4 MINUTES OF THE MEETING HELD ON 15<sup>th</sup> JANUARY 2020**

Working together to improve Health and Wellbeing

4.1 The Minutes of the meeting held on 15<sup>th</sup> January 2020 were agreed as a correct record.

4.2 **Review of action points**

Others are listed under Agenda Item 5: Matters Arising

**5 Matters Arising**

5.1 **Oramorph – post surgical procedures**

JB has raised for 'short term use only' issue with the dispensary at T&ST.

SM has raised at the YDH meeting.

YDH are currently finalising a patient information leaflet which stress's for 'short term use only'.

5.2 **Patients prescribed multiple antipsychotics in Primary Care**

The audit report is currently on hold, and has not yet been seen.

**To follow up and feedback once final audit report is published.**

**Action: SDB**

5.3 **Carbon Footprint of Inhalers**

Trusts to share data for Dry Powder Inhaler (DPI) dispensing and use to compare with the national benchmark

**To share YDH data usage.**

**Action: AP**

5.4 **PBR excluded drug monitoring**

YDH to update on use of cost-effective growth hormone drugs

Feedback from YDH paediatricians is that patients are initiated in Bristol, on a wide variety of brands. It is then a challenge to switch these patients; the parents of these patients are also reluctant for a switch.

Advice was to encourage YDH to empower clinicians in the trust to make these switches.

Omnitrope is the most cost-effective growth hormone.

**Jean-Contracts Lead for Bristol, to raise this issue with Bristol Action: JP**

5.5 **Concerta XL**

Support between secondary and primary care is trying to be established, to enable the switching between bio-equivalent methylphenidate preparations to take place smoothly.

It has been discussed at the Mental Health D&TC. SDB felt that there is still in-house work to be done.

**6 Other Issues for Discussion**

6.1 **Brexit: Latest News - PSNC Main site**

-Nothing to raise

6.2 **Specialist Pharmacy Service SPS  
Covid-19-coronavirus medicines summaries**

Highlighted to ensure all guidance is reviewed and aligned with updates.  
SDB and AP agreed acute trusts are aware.  
-Noted

**6.3 The use of oral medication for symptom control EOL COVID medication for formal ratification**

Feedback received - not many EOL packs needed to be used.  
-Noted

**7 Other Issues for Noting**

**7.1 UKMHRA Alert: Dexamethasone**

Evidence base was for in-patients in acute trusts.  
This is a secondary care treatment option.  
-Noted

**8 Additional Communications for Noting**

**8.1 Pregabalin and opioids - safety update**

-Noted

**8.2 MHRA Central Alerting system Diamorphine injection supply disruption alert (SDA)**

-Noted

**8.3 RMOG National guidance to deprescribe Vitamin B and stop thiamine after 6 weeks**

It was highlighted that the 'deprescribing of vitamin B compound' preparations is one of the primary care Scorecard Indicators for 2020/21. Hoping to see a significant reduction in vitamin B prescribing.  
-Noted

**8.4 Oramorph - alcohol content safety concern**

-Noted

**8.5 Proxy access goes live at EMIS practices**

-Noted

**8.6 CHICO - able to continue recruiting practices to CHICO until April 2020**

-Noted

**8.7 Discontinuation of Mepradec 20mg**

-Noted

**8.8 Methotrexate but no folic acid in last 210 days**

-Noted

**8.9 PCN indicators now on Eclipse Live**

-Noted

**8.10 Primary care AMR Q3 2019-20 update - Prescribing targets, Formulary &**

- Dipstick testing**  
-Noted
- 8.11 **Somerset CCG Medicines Management Newsletter - April 2020**  
-Noted
- 8.12 **Hypertensive patients prescribed soluble painkillers**  
-Noted
- 8.13 **Patients prescribed 6 + SABAs – Dec`19 data**  
It was highlighted that good progress made in our region around the respiratory indicators.  
-Noted
- 8.14 **Mixed inhaler use: Dual metered dose inhalers (MDI) +dry powder inhaler (DPI) patients.**  
-Noted
- 8.15 **Montelukast and neuropsychiatric events**  
-Noted
- 8.16 **Final Guidance on switching from Warfarin to DOACs**  
This was a COVID related action in primary care.  
Around 2-3000 patients have been switched. This has incurred increasing costs and also raised safety issues around renal function and the lack of up-to-date CrCl monitoring obtained to ensure correct dosing.  
-Noted
- 8.17 **Health Service Executive (HSE) Advice about Anti-Inflammatory medication and COVID-19**  
-Noted
- 8.18 **EMIS clinical system and Paramedic prescribing**  
A safety issue to note is that Independent prescribers cannot prescribe any schedule of controlled drugs. The GP practice clinical system doesn't have a functionality to alert / prevent Paramedics from prescribing CDs.  
Community pharmacies have a role to play in identifying this issue should they be presented with a prescription, and alerting the relevant health professionals.  
-Noted
- 8.19 **DHSC Supply Issues Monthly Update May/June 2020**  
-Noted
- 8.20 **Additional guidance switching from Warfarin to Apixaban and rivaroxaban**  
-Noted
- 8.21 **C0546 Electronic repeat dispensing letter**  
-Noted
- 8.22 **Prescribing leads conference - presentation**

-Noted

8.23 **New pathways and resources for care homes and the community to support with malnutrition**

-Noted

8.24 **Dipstick & link to UTI antibiotics in over 65s - week 22 update**

-Noted

8.25 **Urgent Diltiazem safety issue**

Following the discontinuation of Slozem earlier in the year there has been an increase in generic prescribing of diltiazem products. Evidence of once daily patients switched to inappropriate dosing products.

SLOZEM was a once a day XL product and so must not be replaced by a SR brand or generic SR prescription as this will give poorer cardiac control if that SR product is prescribed once a day. Advice to continue to prescribe XL products by brand once daily and SR products by brand twice daily as per guidance. This excludes the regular release diltiazem.

AP informed YDH prescribe by brand.

Acute trusts to raise formulary recommended brands.

-Noted

8.26 **Codes for Care home residents**

-Noted

8.27 **DHSC MSN Latest June 2020**

-Noted

8.28 **DHSC Supply Issues Monthly Update July 2020**

-Noted

8.29 **Sub Optimal Statins**

-Noted

**9 Formulary Applications**

**Arovi<sup>®</sup> (Enoxaparin sodium), ROVI Biotech Ltd.**

9.1 Biosimilar Enoxaparin – a 100% switch would save 85k.

**Request to bring back to March meeting for an update on trusts decision**

YDH informed the group they will continue to use Clexane, and will re-visit option of switching in September.

To inform MMT if they were to switch.

SG highlighted that if prescribed generically, community pharmacy could dispense different brand / device, the patient may not have been trained to use another type of device, thus creating potential delay in patient use.

9.2 **Thicken Aid<sup>®</sup> starch thickener, Aymes International Ltd.**

Agreed March PAMM. 1st line choice on SIP feed formulary.

-Noted

- Omeprazole powder for oral suspension.**  
 9.3 Rosemont Pharmaceuticals Ltd.  
 2mg/ml (£92.17), 4mg/ml (£178.35), 170ml total once constituted.  
 Agreed March PAMM. Not Recommended  
 -Noted
- Hydrogen peroxide 1% cream 25g £8.07 (Crystacide®)** Reig Jofre UK Ltd  
 9.4 For people with localised non-bullous impetigo who are not systemically unwell or at high risk of complications  
 As per [NG153] Impetigo: antimicrobial prescribing  
 Agreed March PAMM. Added to formulary and TLS **GREEN**  
 -Noted
- Bydureon® (Exenatide)**, AstraZeneca UK Ltd.  
 9.5 2mg powder and solvent for sustained-release suspension for injection in pre-filled pen, 4=£73.36.  
 Indicated for Type II diabetes as an adjunct to other hypoglycaemics, including basal insulin, when these plus diet and exercise are inadequate.  
 Agreed March PAMM. Added to formulary and TLS **GREEN**  
 -Noted
- Xeljanz® ▼ (Tofacitinib citrate) 11mg prolonged-release tablets**, Pfizer Ltd.  
 9.6 Indicated with methotrexate for moderate to severe active rheumatoid arthritis when DMARDs are inadequate or not tolerated, or as monotherapy when methotrexate is inappropriate or not tolerated. With methotrexate for active psoriatic arthritis when DMARDs are inadequate or not tolerated.  
 Agreed March PAMM. Added to TLS **RED**  
 -Noted
- Zintasa® (Mesalazine) 400mg enteric-coated tablets**, Morningside Healthcare Ltd. £15.50 (120 tablets).  
 9.7 Mild to moderate ulcerative colitis. Maintenance of remission in ulcerative colitis.  
 Agreed March PAMM. Added to formulary and TLS **GREEN**  
 -Noted
- Ritalin XL® (Methylphenidate) modified-release capsules**, Sandoz Ltd.  
 9.8 Not our preferred brand.  
 Agreed March PAMM. Added to TLS **AMBER**  
 -Noted
- Lenzetto® (Estradiol) 1.53mg per metered dose transdermal spray**, Gedeon Richter (UK) Ltd. £6.90 per 8.1ml (56 actuations).  
 9.9 HRT for oestrogen deficiency symptoms in postmenopausal women at least 6 months after last menses or surgical menopause.  
 Agreed May PAMM. Added to formulary & TLS **GREEN**  
 -Noted
- Suliqua® (Insulin glargine plus Lixisenatide) solution for subcutaneous injection in pre-filled pens**, Aventis Pharma Limited.  
 9.10 100iu/33 microgram per ml, 3 x 3ml SoloStar pre-filled pen=£48.60.  
 100iu/50 microgram per ml, 3 x 3ml SoloStar pre-filled pen=£67.50.  
 With metformin for type II diabetes inadequately controlled by metformin alone or

metformin in combination with another oral hypoglycaemic or basal insulin.  
Agreed May PAMM. Added to formulary & TLS **AMBER**  
-Noted

#### 9.11 **Upadacitinib for RA**

Donna Yell explained the pre-NICE arrangement offered to YDH at a reduced price ahead of NICE.

Used in line with current 3<sup>rd</sup> line options. YDH have signed up to commercial arrangement SPF to rubber stamp. (AbbVie Companies sponsors)

Approved pre-NICE, for patients who can't get on with others in that category  
3<sup>rd</sup> line oral RED drug

**Add to TLS RED NB pre-NICE**

**Action: CT**

#### 10 **DTC decisions and other reports**

**Somerset Partnership Mental Health D&TC** – – Last meeting's 20/03/20- Minutes received / **key points below** and 22/05/20 -Minutes received/ **key point below**

Developing a Shared Care Guideline for agomelatine.

SDB informed the group there is a Mental Health Specialist involved and hopefully the draft document will be ready to bring to the next PAMM meeting.

Contingency plans have been put in place to ensure that clozapine clinics continue, in the event that pharmacy technician staffing levels fall due to self-isolation. The clinics would be extended throughout the week, from 2days to 4 days. With regard to Clozapine supplies, which are dependent on having a valid blood test, guidance has been received from CPMS. So far, the contingency plans haven't been needed to be activated.

*Post-meeting note: Guidance issued to staff involved with clozapine clinics and a patient version also made available.*

#### 10.1

SDB - Melatonin is not a cost effective use of NHS resources.

SDB reported that Concerta XL is still being prescribed a lot in primary care. CH advised that patients are being started on Concerta XL, then switched to a different drug, the patient deteriorates and then the parents want to switch back to Concerta. The most cost effective options are Delmosart, Matoride XL, Xaggitin XL, or Xenidate,XL. The Group discussed how we can address this as there is potentially £80,000 worth of savings to be had in Somerset. It was agreed that SDB would send a Memo initially to CAMHS prescribers and raise this through the D&T Groups at Musgrove and YDH.

SDB informed the group Musgrove Mental Health are working on a Position Statement for methylphenidate prescribing.

Moxifloxacin eye drops for bacterial conjunctivitis as a second or third line treatment, where chloramphenicol or levofloxacin eye drops have failed.

Requested Consultant Ophthalmologist. Approved

-Noted

**YDH Medicines Committee meeting** - Last meeting's 07/02/2020 (**key points below**) & 05/06/2020- Minutes not received.

#### 10.2 SJM attended February's meeting and fed back:

YDH are in agreement with stopping shower and bath emollients.

A discussion was had around sip feeds in patients with BMI>25 – they think that

the junior doctors are putting these on the discharge summaries and they are also supplied by the kitchen rather than the pharmacy. They are going to do some training with the junior doctors and speak to the dieticians.

YDH will not commission Strontium if it is a **RED** drug.

SJM has discussed the HG policy with Juliette Turton who has updated the policy to align with RGOG guidance.

AP informed the group there had been no formulary applications as an outcome from June's meeting.

Donna Yell has requested CT receive the Minutes of the group.

June Meeting notes to follow.

-Noted

10.3 **T&S D&TC** – Last meetings 14/02/20 & 22/05/20 - Minutes not received

-Noted

10.4 **T&S Antimicrobial Prescribing Group** – Last Meeting 12/02/2020 Minutes received (**key points below**) & 06/05/20 - Minutes not received  
Ophthalmology Guidelines: have created guidelines for Antibiotic prescribing in Ophthalmology based this on the Moorfield Guidance. It was agreed that Levofloxacin eye drops would be used in preference to moxifloxacin, however moxifloxacin eye drops would be occasionally required. D&TC submission

-Noted

10.5 **RUH Bath D&TC** – Last meetings 13/02/20 – Minutes received (**key points below**), 12/03/20 & 09/04/20 – Minutes not received

New drug applications:

Letrozole (multiple generics) for anovulatory infertility (unlicensed/off-label use] *Noted that application was in the GWH format and had followed successful application for inclusion on their formulary for 2nd line treatment of patients with anovulatory infertility unresponsive to clomifene and that it had subsequently been identified that RUH fertility services were prescribing using FP10s*

The group were therefore supportive of letrozole being included on the formulary for use in this indication.

-Noted

10.6 **BNSSG Area Prescribing Medicines Optimisation Committee – (Replaced D&TC)**

Last meetings 06/02/20, 02/04/20, 11/06/20 - Draft February minutes received (**key points**)

Signed off guidance on switching patients from warfarin to DOACs

-Noted

10.7 **BNSSG Adult Joint Formulary Group** –meeting 14/01/20 (**key points**)

Approved in principle a change of TLS for Mycophenolate and

Mycophenolic acid (oral) from **RED** to **AMBER** 1 month – Requesting that it be included in the DMARD monitoring local enhanced service and asking

Rheumatology to provide a shared care protocol.

Had an application to change Apomorphine (ApoGo) pens and syringes TLS from **RED** to **AMBER** shared care 3 months and agreed that it should remain

**RED** for the time being.

Last meeting 03/03/20 -Minutes not received

Last meeting 02/06/20 - Minutes received (**Key points**)

Betamethasone soluble tablets - Primary care guidance for GPs produced. This will be presented at APMOC.

Noqdirna (desmopressin oral lyophilisate) for patients over 18 years old for the symptomatic treatment of nocturia due to idiopathic nocturnal polyuria

1. Desmopressin to be included to the formulary as TLS Amber 3 months, pending development of a SCP.

2. To contact the applicant regarding the submitted algorithm to explore the possibility of adapting for use in Primary Care to support ongoing review.

Monitoring recommendations would also need clarifying.

-Noted

#### 10.8 **RMOC function on SPS website**

Paused whilst in pandemic situation.

-For information

### **Part 2 - Items for Information or Noting**

#### 11 **NICE Guidance March, April, May and June 2020**

-Noted

#### 12 **NICE Technology Appraisals**

##### 12.1 **[TA618] Atezolizumab with carboplatin and nabpaclitaxel for untreated advanced non-squamous nonsmall-cell lung cancer (terminated appraisal)**

NICE is unable to make a recommendation

Terminated appraisal. Included in TLS

-Noted

##### 12.2 **[TA619] Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer - New**

Included in TLS as **RED** drug

-Noted

##### 12.3 **[TA620] Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer**

This guidance replaces TA381

Included in TLS as **RED** drug

-Noted

##### 12.4 **[TA621] Osimertinib for untreated EGFR mutation-positive nonsmall-cell lung cancer – New**

Osimertinib is **not recommended**, within its marketing authorisation, for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) in adults.

Not Recommended in TLS

- Noted

- 12.5 **[TA622] Sotagliflozin with insulin for treating type 1 diabetes - New**  
 In adults with a body mass index (BMI) of at least 27 kg/m<sup>2</sup>, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy. Sotagliflozin is not yet available in the NHS, but the company anticipates that it will be available to the NHS in England and Wales within 12 months of guidance publication. Therefore the period of time the NHS has to comply with these recommendations has been extended.  
 Approved. CCG Commissioned
- To add to formulary and TLS GREEN drug, when product is launched (not listed in July Drug Tariff)** **Action: CT / DW**  
 -Noted
- 12.6 **[TA623] Patiomer for treating hyperkalaemia – New**  
 Included in TLS as RED drug  
 - Noted  
 YDH are currently looking into this with their clinicians
- 12.7 **[TA624]Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis in adults - New**  
 Included in TLS as RED drug  
 -Noted
- 12.8 **[TA 625] Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal)**  
 NICE is unable to make a recommendation  
 Terminated appraisal. Included in TLS  
 -Noted
- 12.9 **[TA627] Lenalidomide with rituximab for previously treated follicular lymphoma – New**  
 Included in TLS as RED drug.  
 -Noted
- 12.10 **[TA597] Dapagliflozin with insulin for treating type 1 diabetes**  
 Published: August 2019 Updated: February 2020  
 Included updated information in TLS as AMBER  
 -Noted
- 12.11 **[TA628] Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer**  
 Included in TLS as RED drug.  
 -Noted
- 12.12 **[TA629] Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab**  
 Included in TLS as RED drug.  
 -Noted
- 12.13 **[TA630] Larotrectinib for treating NTRK fusion-positive solid tumours**  
 Included in TLS as RED drug.  
 -Noted

- 12.14 **[TA631] Fremanezumab for preventing migraine**  
 Included in TLS as **RED** drug.  
 Patient access scheme  
 YDH have not received any enquires around this.  
 -Noted
- 12.15 **[TA632] Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer - New**  
 Noted. Positive Appraisal. NHS England Commissioned  
 Approved  
 Add to TLS **RED** Drug **Action: CT**
- 12.16 **[TA633] Ustekinumab for treating moderately to severely active ulcerative colitis - New**  
 Noted. Positive appraisal. CCG Commissioned.  
 Approved  
 Add to TLS **RED** drug **Action: CT**
- 12.17 **[TA626] Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure – New**  
 Noted. Positive appraisal. CCG Commissioned.  
 Approved  
 Add to TLS **RED** drug **Action: CT**
- 12.18 **[TA637] Ranibizumab for treating diabetic retinopathy (terminated appraisal)**  
 -Noted  
 Not for routine commission yet.  
 SG highlighted AP may want to raise awareness to YDH ophthalmologists.  
 Add to TLS NICE **terminated appraisal** **Action: CT**
- 12.19 **[TA636] Eculizumab for treating refractory myasthenia gravis (terminated appraisal)**  
 -Noted  
 Add to TLS NICE **terminated appraisal** **Action: CT**
- 12.20 **[TA635] Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal)**  
 -Noted  
 Add to TLS NICE **terminated appraisal** **Action: CT**
- 12.21 **[TA634] Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal)**  
 -Noted  
 Add to TLS NICE **terminated appraisal** **Action: CT**
- 12.22 **[TA638] Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer - New**  
 Noted. Positive appraisal. NHS England Commissioned.  
 Approved  
 Add to TLS **RED** drug **Action: CT**

- 12.23 **[TA639] Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer - New**  
Noted. Positive appraisal. NHS England Commissioned.  
Approved  
**Add to TLS RED drug** **Action: CT**

### **13 NICE Clinical Guidance**

- 13.1 **COVID-19 – Rapid guidelines and evidence summaries**  
-Noted
- 13.2 **[CG137] Epilepsies: diagnosis and management**  
Published January 2012 **Updated: February 2020**  
-Noted
- 13.3 **[CG185] Bipolar disorder: assessment and management**  
Published: September 2014 **Updated: February 2020**  
Amended recommendations in line with the MHRA guidance on valproate use by women and girls.  
-Noted
- 13.4 **[CG 192] Antenatal and postnatal mental health: clinical management and service guidance**  
Published: December 2014 **Updated: February 2020**  
Amended recommendations on anticonvulsants for mental health problems in line with the MHRA guidance on valproate use by women and girls.  
-Noted
- 13.5 **[NG80] Asthma: diagnosis, monitoring and chronic asthma management**  
Published: November 2017 **Updated: February 2020**  
Reviewed the evidence on increasing the dose of inhaled corticosteroids within a self-management programme in children and young people with asthma and removed a recommendation. New recommendations on self-management in children and young people.  
-Noted
- 13.6 **[NG88] Heavy menstrual bleeding: assessment and management**  
Published: March 2018 **Updated: March 2020**  
This guideline covers assessing and managing heavy menstrual bleeding (menorrhagia). It aims to help healthcare professionals investigate the cause of heavy periods that are affecting a woman's quality of life and to offer the right treatments, taking into account the woman's priorities and preferences.  
-Noted
- 13.7 **[NG29] Intravenous fluid therapy in children and young people in hospital**  
Published date: December 2015 **Updated: June 2020**  
Amended a recommendation to clarify the use of isotonic crystalloids for routine maintenance in term neonates.  
-Noted
- 13.8 **[NG151] Colorectal cancer**  
Updates and replaces NICE guideline CG131 (November 2011) and NICE

guideline CSG5 (June 2004).

Guideline covers managing colorectal (bowel) cancer in people aged 18 and over. It aims to improve quality of life and survival for adults with colorectal cancer through management of local disease and management of secondary tumours (metastatic disease).

-Noted

13.9 **[NG152] Leg ulcer infection: antimicrobial prescribing – New**

This guideline sets out an antimicrobial prescribing strategy for adults with leg ulcer infection. It aims to optimise antibiotic use and reduce antibiotic resistance.

-Noted

13.10 **[NG153] Impetigo: antimicrobial prescribing – New**

Sets out an antimicrobial prescribing strategy for adults, young people and children aged 72 hours and over with impetigo. It aims to optimise antibiotic use and reduce antibiotic resistance.

In line with this guidance Somerset CCG have added hydrogen peroxide 1% cream (Crystacide®) to formulary and TLS **GREEN**

-Noted

13.11 **[NG154] Neonatal parenteral nutrition – New**

Guideline covers parenteral nutrition (intravenous feeding) for babies born preterm, up to 28 days after their due birth date and babies born at term, up to 28 days after their birth. Parenteral nutrition is often needed by preterm babies, critically ill babies, and babies who need surgery.

-Noted

13.12 **[NG 155] Tinnitus: assessment and management – New**

Guideline covers the assessment, investigation and management of tinnitus in primary, community and secondary care. It offers advice to healthcare professionals on supporting people presenting with tinnitus and on when to refer for specialist assessment and management.

-Noted

13.13 **[NG 156] Abdominal aortic aneurysm: diagnosis and management**

This guideline covers diagnosing and managing abdominal aortic aneurysms. It aims to improve care by helping people who are at risk to get tested, specifying how often to monitor asymptomatic aneurysms, and identifying when aneurysm repair is needed and which procedure will work best.

-Noted

13.14 **[NG157] Joint replacement (primary): hip, knee and shoulder-New**

SG highlighted it would be worth trusts looking at the recommendations on tranexamic acid use so they are aware.

-Noted

13.15 **[NG 158] Venous thromboembolic diseases: diagnosis, management and thrombophilia testing**

SG informed the group that Somerset CCG have not implemented this guideline within the DVT pathway.

Trusts were asked if they have implemented.

YDH haven't looked at this as not aware, Andrew Prowse thanked Shaun for

bringing to his attention. They have an anticoagulant pharmacist joining them for one year; this will be tasked to them.

The Somerset CCG DVT pathway will be reviewed if necessary.

-Noted

- 13.16 **[NG159] COVID-19 rapid guideline: critical care in adults**  
Published date: 20 March 2020 Last updated: 29 April 2020  
-Noted
- 13.17 **[NG160] COVID-19 rapid guideline: dialysis service delivery**  
Published date: 20 March 2020 Last updated: 21 May 2020  
-Noted
- 13.18 **[NG161] COVID-19 rapid guideline: delivery of systemic anticancer treatments**  
Published date: 20 March 2020 Last updated: 27 April 2020  
-Noted
- 13.19 **[NG162] COVID-19 rapid guideline: delivery of radiotherapy**  
-Noted
- 13.20 **[NG163] COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community**  
Published date: 03 April 2020 Last updated: 30 April 2020  
-Noted
- 13.21 **[NG164] COVID-19 rapid guideline: haematopoietic stem cell transplantation**  
-Noted
- 13.22 **[NG165] COVID-19 rapid guideline: managing suspected or confirmed pneumonia in adults in the community**  
Published date: 03 April 2020 Last updated: 23 April 2020  
-Noted
- 13.23 **[NG166] COVID-19 rapid guideline: severe asthma**  
-Noted
- 13.24 **[NG167] COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders**  
Published date: 03 April 2020 Last updated: 2 July 2020  
-Noted
- 13.25 **[NG168] COVID-19 rapid guideline: community-based care of patients with chronic obstructive pulmonary disease (COPD)**  
-Noted
- 13.26 **[NG169] COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response**  
Published date: 09 April 2020 Last updated: 30 April 2020  
-Noted
- 13.27 **[NG170] COVID-19 rapid guideline: cystic fibrosis**

- Noted
- 13.28 **[NG171] COVID-19 rapid guideline: acute myocardial injury**  
-Noted
- 13.29 **[NG172] COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response**  
-Noted
- 13.30 **[NG173] COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital**  
-Noted
- 13.31 **[NG174] COVID-19 rapid guideline: children and young people who are immunocompromised**  
-Noted
- 13.32 **[NG175] COVID-19 rapid guideline: acute kidney injury in hospital**  
-Noted
- 13.33 **[NG176] COVID-19 rapid guideline: chronic kidney disease**  
-Noted
- 13.34 **[NG177] COVID-19 rapid guideline: interstitial lung disease**  
-Noted
- 13.35 **[NG178] COVID 19 rapid guideline: renal transplantation**  
-Noted
- 13.36 **[ES28] COVID-19 rapid evidence summary: vitamin D for COVID-19**  
-Noted
- 13.37 **Early access to medicines scheme (EAMS) scientific opinion: Remdesivir in the treatment of patients hospitalised with suspected or laboratory-confirmed SARS-CoV-2 infection who meet the clinical criteria**  
None used yet  
-Noted
- 13.38 **Epidyolex reclassified to Schedule V of the Misuse of Drugs Regulations 2001**  
Highlighted the change to Schedule 5 of the Misuse of Drugs Regulations 2001.  
Flagged to trusts  
-Noted
- 14 Specialist Commissioning**  
Everything transferred into a block-commissioning arrangement  
-Nothing to note
- 15 PBR excluded drug monitoring**
  - 15.1 TST
  - 15.2 YDH

PBR data review is currently paused as we are in a block contract

YDH switched some infusion patients to homecare self-injection, which has been successful and the feedback has been positive about the switch.  
No patients were switched from injections to oral RA

Data to be brought back to SPF meetings

**To share data with JP, and add to Septembers agenda**

**Action: Donna Yell / CT**

**16 Biosimilars**

-Nothing to note

**17 Horizon Scanning**

**17.1 NICE forward planner**

Potentially a plethora of new NICE items coming out  
-Noted

**17.2 SPS New Medicines Newsletter May and June 2020** Standing item

The Newsletters contain useful information around items in development.  
Anyone who would like to raise bring to September's meeting  
-Noted

**18 Risk review and management**

**18.1 Risk review and Management – COVID 19**

The pharmacy and medicines cell looks at supply shortages, supply of palliative medicines, ICU medicines, High cost drugs spend.  
Over the last few weeks and months risk has reduced.  
Nothing major to look at from a risk point of view.  
-Noted

**19 Safety items, PSA Alerts and Signals**

**19.1 MHRA Drug Safety Update Jan, Feb, March, April, May and June**

-Noted

**19.2 MHRA guidance on coronavirus (COVID-19)**

-Noted

**19.3 NPSA Risk of harm to babies and children from coin/button batteries in hearing aids and other hearing devices**

-Noted

**19.4 Convex two-piece skin barriers (Natura /Surfit / Combihesive Wafers)**

-Noted

**19.5 E-cigarette use or vaping: reporting suspected adverse reactions including lung injury**

-Noted

- 19.6 **Ondansetron: small increased risk of oral clefts following use in the first 12 weeks of pregnancy**  
-Noted
- 19.7 **Mecasermin (Increlex<sup>®</sup>▼): risk of benign and malignant neoplasia**  
-Noted
- 19.8 **EMA suspends Ingenol mebutate gel (Picato<sup>®</sup>▼) precaution while review of skin cancer risk continues**  
-Noted
- 19.9 **Lemtrada<sup>®</sup>▼ (alemtuzumab): updated restrictions and strengthened monitoring requirements following review of serious cardiovascular and immune-mediated reactions**  
-Noted
- 19.10 **Valproate (Epilim<sup>®</sup>▼, Depakote<sup>®</sup>▼) pregnancy prevention programme: updated educational materials**  
-Noted
- 19.11 **Nexplanon<sup>®</sup> (etonogestrel) contraceptive implants: new insertion site to reduce rare risk of neurovascular injury and implant migration**  
-Noted
- 19.12 **Esmya (ulipristal acetate): suspension of the licence due to risk of serious liver injury**  
-Noted
- 19.13 **Tofacitinib (Xeljanz<sup>▼</sup>): new measures to minimise risk of venous thromboembolism and of serious and fatal infections**  
-Noted
- 19.14 **Baricitinib (Olumiant<sup>▼</sup>): risk of venous thromboembolism**  
-Noted
- 19.15 **SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness**  
-Noted
- 19.16 **Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression.**  
-Noted
- 19.17 **Class 2 Medicines Recall: Emerade 300 micrograms solution for injection in pre-filled syringe, PL 33616/0014 (EL(20)A/20)**  
-Noted
- 19.18 **NIHR Signal: Increasing omega-3 intake does not prevent depression or anxiety**  
-Noted

- 19.19 **NIHR Signal: Melatonin shows potential for reducing delirium among older people after surgery**  
-Noted
- 19.20 **Coronavirus (COVID-19): new dedicated Yellow Card reporting site for medicines and medical devices**  
-Noted
- 19.21 **Valproate Pregnancy Prevention Programme: temporary advice for management during coronavirus (COVID-19)**  
-Noted
- 19.22 **Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19)**  
-Noted
- 19.23 **Cyproterone acetate: new advice to minimise risk of meningioma**  
-Noted
- 19.24 **Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents**  
As previously mentioned in point 8.16  
Safety issues flagged to primary care, in that a few 100 patients who are not on the right dose; this is flagged by our normal monitoring using Eclipse.  
-Noted
- 20 BNF Changes**
- 20.1 **BNF Update March, April, May, June**  
Follow on from MHRA alerts, medicines being withdrawn or having changes.  
-Noted
- 21 Confirm completion of conflicts of interest training**  
**Send out to SPF main group members the on-line link and details**  
**Action: CT – actioned 09.07.2020**
- 22 Any other business**  
Jon Beard is retiring at the end of next week.  
SPF members send him our very best wishes and grateful thanks for many years of service.
- 22.1 AT will send a card.  
Mark Ashley to be invited as Jon's replacement.  
**Add MA to SPF main group distribution list** **Action: CT**
- Date of Next Meetings:**  
Wednesday 9<sup>th</sup> September 2020  
Wednesday 11<sup>th</sup> November 2020

